Acceleron Pharma

Investors & Media

Press Releases

Date Title and Summary
Toggle Summary Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension
- The PULSAR trial achieved its primary endpoint: a statistically significant reduction in pulmonary vascular resistance - - The trial also achieved statistically significant improvements in the key secondary endpoint of six-minute walk distance (6MWD) and other secondary endpoints, including
Toggle Summary Acceleron Announces Change to Executive Management Team
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 23, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that John Quisel , J.D., Ph.D, Executive Vice
Toggle Summary New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial
Data from MEDALIST showed significant clinical benefit of Reblozyl in treating anemia in adults with myelodysplastic syndromes PRINCETON, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 9, 2020-- Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc.
Toggle Summary Acceleron to Participate in the 38th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 6, 2020-- Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that senior management will participate at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California . On Monday, January 13, 2020 , Habib Dable , Acceleron’s President and
Toggle Summary Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement
Fulcrum to receive $10 million upfront payment and be eligible for future milestone payments CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 30, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat
Toggle Summary Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting
Initial results from phase 2 study evaluating an investigational use of luspatercept-aamt in myelofibrosis-associated anemia showed promising clinical activity – companies plan to initiate pivotal, phase 3 study called INDEPENDENCE in 2020 Longer-term follow-up from pivotal phase 3 studies of
Toggle Summary Acceleron Appoints Jay T. Backstrom, M.D., M.P.H., to Newly Created Role as Head of Research and Development
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 9, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Jay T.
Toggle Summary Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)
PRINCETON, N.J. & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 6, 2019-- Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that following the late-cycle review meeting on December 4, 2019 , they were notified by the U.S.
Toggle Summary Acceleron Appoints Global Innovation and Drug Development Executive Kemal Malik, MB BS, to its Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 6, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Kemal Malik, MB BS, to its Board
Toggle Summary Acceleron Named a “Most Honored” Company in Institutional Investor 2020 “All-America Executive Team” Rankings
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 4, 2019-- Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that it has been included in the recently released